Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RSV preF-based Vaccine Formulations in Adults 60+
NCT05327816Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2022
- Primary completion
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Ad26.RSV.preF and RSV preF Protein in respiratory syncytial virus infection (RSV) (19 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Serious Adverse Events, Number of Participants With Adverse Events of Special Interest and 2 more. Started Apr 2022; status: terminated.
02
Drugs
Ad26.RSV.preFRSV preF Protein
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05327816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327816.